Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Prometheus Biosciences

Request full access

Committed to the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune disease

San Diego, United StatesFounded 1995Biotech & Life Sciences

At a glance

Status
Listed
Listing
IPO 2021

Prometheus Biosciences in the San Diego ecosystem

Live from Dealroom

The Prometheus Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later10 investors entered at this stage

  • Ascend Global Investments
  • Nestlé
  • Cowen Group
  • RTW Investments
  • Eventide Asset Management
  • Perceptive Advisors
  • Cormorant Capital
  • Cedars-Sinai
  • Irving Investors
  • Point72
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Patents

Estimated portfolio value
$52M

57 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Prometheus Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.